Look through the key statistics analysis before diving in deeper into our report:
| Parameter | Current result | Assessment |
|---|---|---|
| Meta title | REVLIMID® (lenalidomide) Treatment for Multiple Myeloma | Mantle Cell Lymphoma | Deletion 5q Myelodysplastic Syndromes | As meta title is a ranking factor, it's quite important to stick to search engine recommended length of aroun 50-60 characters. This website's meta title is 118 characters long. |
| Description | About REVLIMID® (lenalidomide) treatment for deletion 5q myelodysplastic syndromes, mantle cell lymphoma and multiple myeloma including full indications, dosing, administration, efficacy, safety & prescribing information. Indication REVLIMID® (lenalidomide) is used with dexamethasone to treat patients with multiple myeloma (MM) REVLIMID® is used to treat patients who have low- or intermediate-1–risk myelodysplastic syndromes (MDS) where part of chromosome 5 is missing (del 5q). These patients have low red blood cell counts (anemia) that require blood transfusions REVLIMID® is used to treat patients with mantle cell lymphoma (MCL) when the disease comes back or becomes worse after treatment with two prior medicines, one of which included bortezomib REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial It is not known if REVLIMID is safe and effective in children under 18 years of age Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide TO REPORT SUSPECTED ADVERSE REACTIONS OR EMBRYO-FETAL EXPOSURE: CONTACT CELGENE CORPORATION AT 1-888-423-5436 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH Important Safety Information + What is the most important information I should know about REVLIMID? Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program. Before prescribing REVLIMID, your healthcare provider will explain the REVLIMID REMS program to you and have you sign the Patient-Physician Agreement Form. REVLIMID may cause serious side effects, including: Possible birth defects (deformed babies) or death of an unborn baby. Females who are pregnant or who plan to become pregnant must not take REVLIMID. REVLIMID is similar to the medicine thalidomide (THALOMID®), which is known to cause severe life-threatening birth defects. REVLIMID has not been tested in pregnant females. REVLIMID has harmed unborn animals in animal testing. Females must not get pregnant: For at least 4 weeks before starting REVLIMID While taking REVLIMID During any breaks (interruptions) in your treatment with REVLIMID For at least 4 weeks after stopping REVLIMID Females who can become pregnant: Must have pregnancy tests weekly for 4 weeks, then every 4 weeks if your menstrual cycle is regular, or every 2 weeks if your menstrual cycle is irregular. If you miss your period or have unusual bleeding, you will need to have a pregnancy test and receive counseling. Must agree to use 2 different forms of effective birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping REVLIMID. Talk with your healthcare provider to find out about options for effective forms of birth control that you may use to prevent pregnancy. If you had unprotected sex or if you think your birth control has failed, stop taking REVLIMID immediately and call your healthcare provider right away. If you become pregnant while taking REVLIMID, stop taking it right away and call your healthcare provider. If your healthcare provider is not available, you can call Celgene Customer Care Center at 1-888-423-5436. Healthcare providers and patients should report all cases of pregnancy to FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation at 1-888-423-5436. There is a pregnancy exposure registry that monitors the outcomes of females who take REVLIMID during pregnancy, or if their male partner takes REVLIMID and they are exposed during pregnancy. You can enroll in this registry by calling Celgene Corporation at the phone number listed above. REVLIMID can pass into human semen. Males, including those who have had a vasectomy, must always use a latex or synthetic condom during any sexual contact with a pregnant female or a female that can become pregnant while taking REVLIMID, during any breaks (interruptions) in your treatment with REVLIMID, and for up to 4 weeks after stopping REVLIMID. If a female becomes pregnant with your sperm, you should call your HCP right away. The baby may be exposed to REVLIMID and may be born with birth defects. Do not have unprotected sexual contact with a female who is or could become pregnant. Tell your healthcare provider if you do have unprotected sexual contact with a female who is or could become pregnant. Do not donate sperm while taking REVLIMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping REVLIMID. Low white blood cells (neutropenia) and low platelets (thrombocytopenia). REVLIMID causes low white blood cells and low platelets in most people. You may need a blood transfusion or certain medicines if your blood counts drop too low. Your healthcare provider should check your blood counts often especially during the first several months of treatment with REVLIMID, and then at least monthly. Tell your healthcare provider if you develop any bleeding or bruising, during treatment with REVLIMID. Blood clots. Blood clots in the arteries, veins, and lungs happen more often in people who take REVLIMID. This risk is even higher for people with multiple myeloma who take the medicine dexamethasone with REVLIMID. Heart attacks and strokes also happen more often in people who take REVLIMID with dexamethasone. To reduce this increased risk, most people who take REVLIMID will also take a blood thinner medicine. Before taking REVLIMID, tell your healthcare provider: If you have had a blood clot in the past If you have high blood pressure, smoke, or if you have been told you have a high level of fat in your blood (hyperlipidemia) About all the medicines you take. Certain other medicines can also increase your risk for blood clots Call your healthcare provider or get medical help right away if you get any of the following during treatment with REVLIMID: Signs or symptoms of a blood clot in the lung, arm, or leg may include: shortness of breath, chest pain, or arm or leg swelling Signs or symptoms of a heart attack may include: chest pain that may spread to the arms, neck, jaw, back, or stomach area (abdomen), feeling sweaty, shortness of breath, feeling sick or vomiting Signs or symptoms of stroke may include: sudden numbness or weakness, especially on one side of the body, severe headache or confusion, or problems with vision, speech, or balance Who should not take REVLIMID? Do not take REVLIMID if you are pregnant, plan to become pregnant, or become pregnant during treatment with REVLIMID. See "What is the most important information I should know about REVLIMID?" Do not take REVLIMID if you are allergic to lenalidomide or any of the ingredients in REVLIMID. See the Medication Guide for a complete list of ingredients in REVLIMID. What should I tell my healthcare provider before taking REVLIMID? Before you take REVLIMID, tell your healthcare provider about all of your medical conditions, including if you: have liver problems have kidney problems or receive kidney dialysis treatment have thyroid problems are lactose intolerant. REVLIMID contains lactose. are breastfeeding. REVLIMID must not be used by females who are breastfeeding. It is not known if REVLIMID passes into your breast milk and can harm your baby. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REVLIMID and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist. How should I take REVLIMID? Take REVLIMID exactly as prescribed and follow all the instructions of the REVLIMID REMS program Swallow REVLIMID capsules whole with water 1 time a day. Do not open, break, or chew your capsules. REVLIMID may be taken with or without food. Take REVLIMID at about the same time each day. Do not open the REVLIMID capsules or handle them any more than needed. If you touch a broken REVLIMID capsule or the medicine in the capsule, wash the area of your body right away with soap and water. If you miss a dose of REVLIMID and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose. Do not take 2 doses at the same time. If you take too much REVLIMID, call your healthcare provider right away. Do not share REVLIMID with other people. It may cause birth defects and other serious problems. What should I avoid while taking REVLIMID? See “What is the most important information I should know about REVLIMID?” Females: Do not get pregnant and do not breastfeed while taking REVLIMID. Males: Do not donate sperm Do not donate blood while you take REVLIMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping REVLIMID. If someone who is pregnant gets your donated blood, her baby may be exposed to REVLIMID and may be born with birth defects. What are the possible side effects of REVLIMID? REVLIMID can cause serious side effects, including: See "What is the most important information I should know about REVLIMID?" Increased risk of death in people who have chronic lymphocytic leukemia (CLL). People with CLL who take REVLIMID have an increased risk of death compared with people who take the medicine chlorambucil. REVLIMID may cause you to have serious heart problems that can lead to death, including atrial fibrillation, heart attack, or heart failure. You should not take REVLIMID if you have CLL unless you are participating in a controlled clinical trial. Risk of new cancers (malignancies). An increase in new (second) cancers has happened in patients who received REVLIMID and melphalan, or a blood stem cell transplant, including certain blood cancers, such as acute myelogenous leukemia (AML), and myelodysplastic syndrome (MDS) and certain other types of cancers of the skin and other organs. Talk with your healthcare provider about your risk of developing new cancers if you take REVLIMID. Your healthcare provider will check you for new cancers during your treatment with REVLIMID. Severe liver problems, including liver failure and death. Your healthcare provider should do blood tests to check your liver function during your treatment with REVLIMID. Tell your healthcare provider right away if you develop any of the following symptoms of liver problems: yellowing of your skin or the white part of your eyes (jaundice) dark or brown (tea-colored) urine pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal feeling very tired Serious allergic reactions and serious skin reactions can happen with REVLIMID and may cause death. Call your healthcare provider right away if you develop any of these signs or symptoms of a serious allergic reaction or serious skin reaction during treatment with REVLIMID: swelling of your face, eyes, lips, tongue, throat trouble swallowing trouble breathing skin rash, hives, or peeling of your skin blisters Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Worsening of your tumor (tumor flare reaction). Tell your healthcare provider if you get any of these symptoms of tumor flare reaction while taking REVLIMID: tender swollen lymph nodes, low grade fever, pain, or rash. Thyroid problems. Your healthcare provider may check your thyroid function before you start taking REVLIMID and during treatment with REVLIMID. The most common side effects of REVLIMID include: diarrhea rash nausea constipation tiredness fever itching swelling of the limbs and skin cough These are not all the possible side effects of REVLIMID. Your healthcare provider may tell you to decrease your dose, temporarily stop or permanently stop taking REVLIMID if you develop certain serious side effects during treatment with REVLIMID. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide | This meta description is 12394 characters in length. Google suggests up to 320 characters at the very most to make sure the whole meta description is visible in search results page. |
| <meta> keywords | REVLIMID, lenalidomide, Treatment, deletion 5q myelodysplastic syndromes, mantle cell lymphoma, Multiple Myeloma, newly diagnosed, indications, dosing, administration, efficacy, prescribing information, mechanism of action, trial design, dosing schedule, dosing modification, celgene | Strangely enough, meta keywords still seem to be used. We would not go down that road unless very carefully - meta keywords have not been known as a positive ranking factor for a while now. |
| Site speed | Around 1.2371 seconds | The website load speed is rather good. |
| Alexa global rank | 1937926, as last checked | Based on Alexa Global, we can assume the website is not very popular. Mind you, Alexa's worth is questionable at best. |
| Quantcast | Current rank, according to our database, is at 436260 | Quantcast does not rank this website very high, which should in theory mean it's not that popular. Having said that, popularity is context-dependant, so take this with a grain of salt. |
| Links on homepage | Around 79 links | This is a well-judged amount of links for a homepage. |
| Backlinks amount | Approximately 65 | The number of backlinks seems awfully low. If possible, the webmaster should work towards building more through quality content and public awareness. |
| HTML size | 105.2KB | A very good result, this. Remember, search engines such as Google place a lot of their website ratings on its speed. |
| Website host server overview | Server status: online. Server IP address for this website is 54.77.219.52. | We apologize, but for some reason we were unable to gather enough data to provide a detailed insight at this time. |
If the basic information we presented you with above is not enough, get ready to dive in much deeper!
Now that the numbers are taken care of, we can go deeper and try to analyse the website from a user's perspective. More specifically, let's see if we can identify the target audience as well as a few related websites and categories.
| Parameter | Current result | Assessment |
|---|---|---|
| Alternative websites | revlimidrems.com celgeneriskmanagement.com celgenepatientsupport.com celgene.com pomalyst.com |
These websites fall into the same categories as revlimid.com, more or less. By extension, they compete with the analysed website for the same target audience. |
Trying to acquire very accurate visitor data is immensely difficult and can only be done when given direct access to the server. However, there are ways to get approximate numbers.
The numbers themselves probably say enough, but we'll add some insight where possible.
| Parameter | Current result | Assessment |
|---|---|---|
| Approximate time on site | 2:18 | Pretty good for an average time spent, wouldn't you say? |
ALEXA rating is based on the number of visitors a given page receives. The higher the visitor count, the higher the rating. Currently, ALEXA has over 4 million websites indexed. If you sense cynicism in our words, you're not mistaken - we think Alexa rating is overrated, to put it mildly. A website's worth (and contextual popularity) is more than the sum of the views. So take the rank with a grain of salt.
QUANTCAST is a data processing company that mostly gathers information for advertising companies. It specializes in real-time audience analysis and, as you may have gathered, is really quite similar to Alexa, if perhaps not as infamous. To our knowledge, the company has rated and ranked approximately 292138858 websites so far. There is always a caveat with these sort of ranking systems - they don't really take any context into account. As such, their usefulness is debatable at best. Don't overthink this rank - it's just a number, really.
Servers are physical storage devices that contain all the files and databases associated with a specific website, sometimes more than one. At times, a server makes up several virtual devices - separate servers used for shared hosting (tends to be cheaper). Entering website address into the address bar of your browser starts the request process during which your browser contacts the server and asks for specific files and database entries in order to display the requested website.
What follows is certainly very geeky, but informative for the knowing. Dig in:
| Header detail |
|---|
HTTP/1.1 200 OK Content-Type: text/html; charset=UTF-8 Date: Sat, 24 Jun 2017 03:20:39 GMT Link: <http://www.revlimid.com/wp-json/>; rel="https://api.w.org/" Link: <http://www.revlimid.com/>; rel=shortlink Server: Apache X-Frame-Options: SAMEORIGIN X-Pingback: http://www.revlimid.com/xmlrpc.php X-XSS-Protection: 1; mode=block transfer-encoding: chunked Connection: keep-alive |
| WHOIS |
|---|
Whois Server Version 2.0
Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.
Domain Name: REVLIMID.COM
Registrar: CSC CORPORATE DOMAINS, INC.
Sponsoring Registrar IANA ID: 299
Whois Server: whois.corporatedomains.com
Referral URL: http://www.cscglobal.com/global/web/csc/digital-brand-services.html
Name Server: NS-1413.AWSDNS-48.ORG
Name Server: NS-1716.AWSDNS-22.CO.UK
Name Server: NS-240.AWSDNS-30.COM
Name Server: NS-650.AWSDNS-17.NET
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Updated Date: 15-aug-2016
Creation Date: 19-aug-2003
Expiration Date: 19-aug-2017
>>> Last update of whois database: Sun, 21 May 2017 04:03:41 GMT <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
Domain Name: revlimid.com
Registry Domain ID: 102280073_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corporatedomains.com
Registrar URL: www.cscprotectsbrands.com
Updated Date: 2016-08-15T05:38:35Z
Creation Date: 2003-08-19T06:23:51Z
Registrar Registration Expiration Date: 2017-08-19T06:23:51Z
Registrar: CSC CORPORATE DOMAINS, INC.
Registrar IANA ID: 299
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone: +1.8887802723
Domain Status: clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited
Registry Registrant ID:
Registrant Name: Domain Administrator
Registrant Organization: Celgene Corporation
Registrant Street: 86 Morris Avenue
Registrant City: Summit
Registrant State/Province: NJ
Registrant Postal Code: 07901
Registrant Country: US
Registrant Phone: +1.9086739000
Registrant Phone Ext:
Registrant Fax: +1.9086739001
Registrant Fax Ext:
Registrant Email:
Registry Admin ID:
Admin Name: Domain Administrator
Admin Organization: Celgene Corporation
Admin Street: 86 Morris Avenue
Admin City: Summit
Admin State/Province: NJ
Admin Postal Code: 07901
Admin Country: US
Admin Phone: +1.9086739000
Admin Phone Ext:
Admin Fax: +1.9086739001
Admin Fax Ext:
Admin Email:
Registry Tech ID:
Tech Name: Domain Administrator
Tech Organization: Celgene Corporation
Tech Street: 86 Morris Avenue
Tech City: Summit
Tech State/Province: NJ
Tech Postal Code: 07901
Tech Country: US
Tech Phone: +1.9086739000
Tech Phone Ext:
Tech Fax: +1.9086739001
Tech Fax Ext:
Tech Email:
Name Server: ns-1413.awsdns-48.org
Name Server: ns-240.awsdns-30.com
Name Server: ns-650.awsdns-17.net
Name Server: ns-1716.awsdns-22.co.uk
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2016-08-15T05:38:35Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
Corporation Service Company(c) (CSC) The Trusted Partner of More than 50% of the 100 Best Global Brands.
Contact us to learn more about our enterprise solutions for Global Domain Name Registration and Management, Trademark Research and Watching, Brand, Logo and Auction Monitoring, as well SSL Certificate Services and DNS Hosting.
NOTICE: You are not authorized to access or query our WHOIS database through the use of high-volume, automated, electronic processes or for the purpose or purposes of using the data in any manner that violates these terms of use. The Data in the CSC WHOIS database is provided by CSC for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. CSC does not guarantee its accuracy. By submitting a WHOIS query, you agree to abide by the following terms of use: you agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via direct mail, e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to CSC (or its computer systems). CSC reserves the right to terminate your access to the WHOIS database in its sole discretion for any violations by you of these terms of use. CSC reserves the right to modify these terms at any time.
Register your domain name at http://www.cscglobal.com |
Now that you are hopefully done with revlimid.com, we invite you to read more of our in-depth reports. Try entering a new domain address in the search form at the top of this page, or on the homepage. Alternatively, refer to this list for more website overviews:
We have found so many alternative TLD extensions for revlimid.com. Here is the full list with 580 entries:
The following list of most frequent domain address mistypes associated with revlimid.com contains at least 1192 entries: